Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Intangibles (2016 - 2025)

Amicus Therapeutics' Intangibles history spans 13 years, with the latest figure at $13.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Intangibles fell 19.09% year-over-year to $13.9 million, compared with a TTM value of $13.9 million through Dec 2025, down 19.09%, and an annual FY2025 reading of $13.9 million, down 19.09% over the prior year.
  • Intangibles for Q4 2025 was $13.9 million at Amicus Therapeutics, down from $14.7 million in the prior quarter.
  • The five-year high for Intangibles was $23.0 million in Q1 2021, with the low at $13.9 million in Q4 2025.
  • Average Intangibles over 5 years is $20.3 million, with a median of $21.7 million recorded in 2023.
  • Year-over-year, Intangibles changed 0.0% in 2021 and then dropped 19.09% in 2025.
  • Tracing FOLD's Intangibles over 5 years: stood at $23.0 million in 2021, then changed by 0.0% to $23.0 million in 2022, then decreased by 10.91% to $20.5 million in 2023, then dropped by 16.07% to $17.2 million in 2024, then dropped by 19.09% to $13.9 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Intangibles are $13.9 million (Q4 2025), $14.7 million (Q3 2025), and $15.6 million (Q2 2025).